New data out of cleveland clinic shows biosig pure ep may be used for more precise approach for $6 billion annual atrial fibrillation market

Westport, ct / accesswire / may 25, 2023 / cleveland clinic researchers presented data from three new studies involving biosig technologies' (nasdaq:bsgm) proprietary pure ep platform at the annual heart rhythm 2023 meeting in new orleans, la, last week. the platform's precision signal-capturing technology is meant to improve the speed, accuracy and precision of cardiac ablation, a widely-used surgery to treat atrial fibrillation.
BSGM Ratings Summary
BSGM Quant Ranking